Cargando…

Detection and Correlation of Single and Concomitant TP53, PTEN, and CDKN2A Alterations in Gliomas

Gliomas are the most frequent primary tumors of central nervous system and represent a heterogeneous group of tumors that originates from the glial cells. TP53, PTEN, and CDKN2A are important tumor suppressor genes that encode proteins involved in sustaining cellular homeostasis by different signali...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pessôa, Igor Andrade, Amorim, Carolina Koury, Ferreira, Wallax Augusto Silva, Sagica, Fernanda, Brito, José Reginaldo, Othman, Moneeb, Meyer, Britta, Liehr, Thomas, de Oliveira, Edivaldo Herculano C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6600458/ https://www.ncbi.nlm.nih.gov/pubmed/31151164 http://dx.doi.org/10.3390/ijms20112658

Ejemplares similares

Meningiomas: An Overview of the Landscape of Copy Number Alterations in Samples from an Admixed Population
por: da Silveira, Michele Amaral, et al.
Publicado: (2020)

Comprehensive analysis of epigenetics regulation, prognostic and the correlation with immune infiltrates of GPX7 in adult gliomas
por: Ferreira, Wallax Augusto Silva, et al.
Publicado: (2022)

Expression of GOT2 Is Epigenetically Regulated by DNA Methylation and Correlates with Immune Infiltrates in Clear-Cell Renal Cell Carcinoma
por: Ferreira, Wallax Augusto Silva, et al.
Publicado: (2022)

Long Noncoding RNA GATA3-AS1 Promotes Cell Proliferation and Metastasis in Hepatocellular Carcinoma by Suppression of PTEN, CDKN1A, and TP53
por: Luo, Xuee, et al.
Publicado: (2019)

Mutation analysis of genes that control the G1/S cell cycle in melanoma: TP53, CDKN1A, CDKN2A, and CDKN2B
por: Soto, José Luis, et al.
Publicado: (2005)

TP53-PTEN-NF1 depletion in human brain organoids produces a glioma phenotype in vitro
por: Singh, Sanjay K., et al.
Publicado: (2023)

Expression Analysis of Genes Involved in the RB/E2F Pathway in Astrocytic Tumors
por: Ferreira, Wallax Augusto Silva, et al.
Publicado: (2015)

NSAIDs Modulate CDKN2A, TP53, and DNA Content Risk for Progression to Esophageal Adenocarcinoma
por: Galipeau, Patricia C, et al.
Publicado: (2007)

TP53 and PTEN as driver mutations in Zenker's carcinoma—a clinical presentation
por: Noel, Zsanett, et al.
Publicado: (2020)

miR-106b regulates the proliferation and differentiation of neural stem/progenitor cells through Tp53inp1-Tp53-Cdkn1a axis
por: Xia, Xiaohuan, et al.
Publicado: (2019)

A novel dic (17;18) (p13.1;q11.2) with loss of TP53 and BCR/ABL rearrangement in an Imatinib resistant chronic myeloid leukemia
por: Al-achkar, Walid, et al.
Publicado: (2012)

Concomitant p53 and PTEN immunoexpression to predict the risk of malignancy in endometrial polyps
por: Abrão, Féres, et al.
Publicado: (2018)

KRAS, TP53, CDKN2A, SMAD4, BRCA1, and BRCA2 Mutations in Pancreatic Cancer
por: Cicenas, Jonas, et al.
Publicado: (2017)

Repurposing auranofin to treat TP53-mutated or PTEN-deleted refractory B-cell lymphoma
por: Wang, Jeffrey, et al.
Publicado: (2019)

Cooperation between liver-specific mutations of pten and tp53 genetically induces hepatocarcinogenesis in zebrafish
por: Luo, Juanjuan, et al.
Publicado: (2021)

Liver cancer with concomitant TP53 and CTNNB1 mutations: a case report
por: Friemel, Juliane, et al.
Publicado: (2016)

Anticancer Potential of Flavonoids: An Overview with an Emphasis on Tangeretin
por: de Luna, Francisco Canindé Ferreira, et al.
Publicado: (2023)

Coexistence of YWHAZ amplification predicts better prognosis in muscle-invasive bladder cancer with CDKN2A or TP53 loss
por: Liu, Shenghua, et al.
Publicado: (2016)

Differential profile of CDKN1A and TP53 expressions in bone marrow mesenchymal stromal cells from myeloid neoplasms
por: Lopes, Matheus Rodrigues, et al.
Publicado: (2016)

Assessment of clinical outcomes with immune checkpoint inhibitor therapy in melanoma patients with CDKN2A and TP53 pathogenic mutations
por: DeLeon, Thomas T., et al.
Publicado: (2020)

TP53 Mutations and CDKN2A Mutations/Deletions are Highly Recurrent Molecular Alterations in the Malignant Progression of Sinonasal Papillomas
por: Brown, Noah A., et al.
Publicado: (2020)

Mitigating the Risk of t-MNs Development: TP53 or Not TP53?
por: Tesio, Melania
Publicado: (2023)

The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis
por: Leroy, Bernard, et al.
Publicado: (2013)

TP53 and PTEN mutations were shared in concurrent germ cell tumor and acute megakaryoblastic leukemia
por: Akizuki, Keiichi, et al.
Publicado: (2020)

Thyroid cancer harboring PTEN and TP53 mutations: A peculiar molecular and clinical case report
por: Colombo, Carla, et al.
Publicado: (2022)

TP53 and CDKN2A mutations in patients with early-stage lung squamous cell carcinoma: an analysis of the correlations and prognostic outcomes
por: Wang, Peiyuan, et al.
Publicado: (2021)

Low penetrance susceptibility to glioma is caused by the TP53 variant rs78378222
por: Enciso-Mora, V, et al.
Publicado: (2013)

Self-Renewing Pten(-/-)TP53(-/-) Protospheres Produce Metastatic Adenocarcinoma Cell Lines with Multipotent Progenitor Activity
por: Abou-Kheir, Wassim, et al.
Publicado: (2011)

Aberrant PTEN, PIK3CA, pMAPK, and TP53 expression in human scalp and face angiosarcoma
por: Wan, Huiying, et al.
Publicado: (2021)

Huaier Inhibits Proliferation, Migration, and Invasion of Cutaneous Squamous Cell Carcinoma Cells by Inhibiting the Methylation Levels of CDKN2A and TP53
por: Wang, Liang, et al.
Publicado: (2021)

TP53 and TP53-associated genes are correlated with the prognosis of paediatric neuroblastoma
por: Wang, Haiwei, et al.
Publicado: (2022)

ACTH-secreting pituitary carcinoma with TP53, NF1, ATRX and PTEN mutations Case report and review of the literature
por: Sumislawski, Piotr, et al.
Publicado: (2022)

Concurrent TP53 and CDKN2A Gene Aberrations in Newly Diagnosed Mantle Cell Lymphoma Correlate with Chemoresistance and Call for Innovative Upfront Therapy
por: Malarikova, Diana, et al.
Publicado: (2020)

Inactivation of RB1 , CDKN2A , and TP53 have distinct effects on genomic stability at side‐by‐side comparison in karyotypically normal cells
por: Andersson, Natalie, et al.
Publicado: (2022)

Optimisation of TP53 reporters by systematic dissection of synthetic TP53 response elements
por: Trauernicht, Max, et al.
Publicado: (2023)

P53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation
por: Zheng, Hongwu, et al.
Publicado: (2008)

Exclusion of the genes CDKN2 and PTEN as causative gene defects in Li–Fraumeni syndrome
por: Burt, E C, et al.
Publicado: (1999)

Expression of p53 and PTEN in human primary endometrial carcinomas: Clinicopathological and immunohistochemical analysis and study of their concomitant expression
por: Stavropoulos, Aggelis, et al.
Publicado: (2019)

The TP53 fertility network
por: Paskulin, Diego d’Avila, et al.
Publicado: (2012)

TP53: an oncogene in disguise
por: Soussi, T, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_gcatk9jdr42k7s2k8io67mnku1